Actively Recruiting

Phase 3
Age: 38Years +
FEMALE
NCT05447208

Effect of GH on the Blastocyst Euploid Rate in AMA Patients

Led by ShangHai Ji Ai Genetics & IVF Institute · Updated on 2025-02-12

400

Participants Needed

1

Research Sites

230 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This randomized trial aims to compare the euploid rate of blastocysts in AMA patients undergoing PGT-A (preimplantation genetic testing for aneuploidy) with or without growth hormone supplement. Infertile patients ≥38 years old will be recruited for study after informed consent if they fulfill the inclusion criteria and do not have the exclusion criteria. Eligible women will be randomised into one of the two groups: Treatment group: Women will receive growth hormone (GH) supplement before and during antagonist protocol for ovarian stimulation. Control group: Women will receive antagonist protocol for ovarian stimulation. The primary outcome is the euploidy rate of blastocysts.

CONDITIONS

Official Title

Effect of GH on the Blastocyst Euploid Rate in AMA Patients

Who Can Participate

Age: 38Years +
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Women aged 38 years or older intending to undergo preimplantation genetic testing for aneuploidy (PGT-A)
  • Body mass index (BMI) within the normal range of 18.50 to 24.0 kg/m2
  • Male partner with normal semen analysis
Not Eligible

You will not qualify if you...

  • Presence of endometriosis grade 3 or higher or untreated hydrosalpinx
  • Uterine abnormalities such as congenital malformations (unicornate, bicornate, or duplex uterus), untreated uterine septum, adenomyosis, submucous myoma, or endometrial polyps
  • Planned or indicated preimplantation genetic testing for structural rearrangement (PGT-SR) or monogenic disorder (PGT-M), including parental abnormal karyotype or diagnosed monogenic disease
  • History of endocrine disorders, autoimmune diseases, or thrombophilia
  • Previous growth hormone supplementation during IVF or use of other supplementary drugs during stimulation
  • Contraindications to growth hormone treatment including active malignancy, history of cancer, diabetic retinopathy, diabetes mellitus, and chronic kidney disease

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Shanghai JIAI Genetics and IVF Institute

Shanghai, Shanghai Municipality, China, 200011

Actively Recruiting

Loading map...

Research Team

Y

YILUN SUI, MD

CONTACT

X

XIAOXI SUN, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here